Merck & Co., Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Merck & Co., Inc. (MRK) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $64.76 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-24
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $64.76, a 6.01% decline from fiscal 2024.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $68.90, a 6.71% increase from fiscal 2023.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $64.57, a 6.25% increase from fiscal 2022.
- Merck & Co., Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $60.77, a 12.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $64.76 10-K · filed 2026-02-24 |
| 2024-12-31 | $68.90 10-K · filed 2025-02-25 |
| 2023-12-31 | $64.57 10-K · filed 2024-02-26 |
| 2022-12-31 | $60.77 10-K · filed 2023-02-24 |
| 2021-12-31 | $54.14 10-K · filed 2022-02-25 |
| 2020-12-31 | $52.73 10-K · filed 2021-02-25 |
| 2019-12-31 | $44.48 10-K · filed 2020-02-26 |
| 2018-12-31 | $40.51 10-K · filed 2019-02-27 |
| 2017-12-31 | $43.38 10-K · filed 2018-02-27 |
| 2016-12-31 | $39.39 10-K · filed 2017-02-28 |
| 2015-12-31 | $35.23 10-K · filed 2016-02-26 |
| 2014-12-31 | $39.71 10-K · filed 2015-02-27 |
| 2013-12-31 | $36.37 10-K · filed 2014-02-27 |
| 2012-12-31 | $29.64 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |